|
|
Volumn 102, Issue 23, 2010, Pages
|
|
Oncologists want FDA to rethink REMS.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANEMIC AGENT;
ANTINEOPLASTIC AGENT;
NARCOTIC ANALGESIC AGENT;
ADDICTION;
CHEMICALLY INDUCED DISORDER;
DOCTOR PATIENT RELATION;
EVALUATION;
FOOD AND DRUG ADMINISTRATION;
GRAFT REJECTION;
HUMAN;
IMMUNOLOGY;
IRON DEFICIENCY ANEMIA;
NEOPLASM;
NOTE;
PAIN;
PRESCRIPTION;
STANDARD;
UNITED STATES;
ANALGESICS, OPIOID;
ANEMIA, HYPOCHROMIC;
ANTINEOPLASTIC AGENTS;
DRUG PRESCRIPTIONS;
EVALUATION STUDIES AS TOPIC;
GRAFT REJECTION;
HEMATINICS;
HUMANS;
NEOPLASMS;
PAIN;
PHYSICIAN-PATIENT RELATIONS;
SUBSTANCE-RELATED DISORDERS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 79952111060
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djq491 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
